References
- O’Brien TP. Emerging guidelines for use of NSAID therapy to optimize cataract surgery patient care. Curr Med Res Opin 2005;21:1131–7
- Gayton JL. A clinical comparison of two different prednisolone acetate formulations in patients undergoing cataract surgery. Curr Med Res Opin 2005;21:1291–5
- Omnipred [package insert]. Fort Worth, TX: Alcon Laboratories, Inc.; 2006
- Pred Forte [package insert]. Irvine, CA: Allergan, Inc., 2001
- FDA Electronic Orange Book. Food and Drug Administration website. Available at: http://www.fda.gov/cder/ob/default.htm (Accessed June 1, 2007)
- Alcon Laboratories, Personal communication, June 1, 2007
- McGhee CNJ, Dean S, Danesh-Meyer H. Locally administered ocular corticosteroids. Benefits and risks. Drug Safety 2002;25:33–55
- Alcon Laboratories (Alcon Lab Notebook Reference LN 13206:022)
- Roberts CW, Nelson PL. Comparative analysis of prednisolone acetate suspensions. J Ocular Pharmacol Ther 2007;23:182–7
- Owen GR, Brooks AC, James O, Robertson SM. A novel in vivo rabbit model that mimics human dosing to determine the distribution of antibiotics in ocular tissues. J Ocular Pharmacol Ther 2007;4:335–42
- Katz JA, Owen GR, Robertson SM, et al. A new in vivo rabbit model that mimics human dosing to determine the distribution of 1.0% prednisolone acetate suspensions in the tears and aqueous humor. Invest Ophthalmol Vis Sci 2007;48:4314
- McGhee CNJ, Watson DG, Midgley JM, et al. Penetration of synthetic corticosteroids into human aqueous humour. Eye 1990;4:526–30